Comparison between patients with and without depressive state
| Clinical factors | Patients with depressive state (n=39) | Patients without depressive state (n=248) |
| Age (years) | 52.3±18.0 | 58.2±16.9 |
| Female | n=28 | n=165 |
| Time since onset (years) | 6.1±6.2* | 9.3±8.4 |
| Age at onset (years) | 46.1±18.7 | 48.3±18.6 |
| Thymectomy | n=12 | n=129 |
| Thymoma | n=7 | n=56 |
| QMG | 9.9±6.6** | 6.6±4.7 |
| Ocular QMG | 2.5±2.2* | 1.6±1.7 |
| Bulbar QMG | 0.5±1.2 | 0.3±0.7 |
| MG composite | 10.4±7.8*** | 5.7±5.5 |
| MG-ADL | 5.3±4.0** | 3.1±2.9 |
| MGFA classification (worst) | I/II/III/IV/V: 7/13/14/2/4 | I/II/III/IV/V: 61/112/46/10/18 |
| Current dose of PSL (mg/day) | 8.1±7.0*** | 4.1±5.6 |
| Maximum dose of PSL (mg/day) | 20.4±21.6 | 20.5±20.6 |
| Calcineurin inhibitors | n=19 | n=96 |
| Crisis | n=4 | n=18 |
| AChR-Ab positivity | n=24 | n=208 |
| Kv 1.4-Ab positivity | n=6 | n=31 |
| Titin-Ab positivity | n=8 | n=45 |
| CSR | n=0 | n=21 |
| PR | n=1 | n=21 |
| MM | n=4 | n=91 |
| I | n=11 | n=80 |
| U | n=13 | n=41 |
| W | n=2 | n=2 |
*p<0.05, **p<0.01, ***p<0.001 (Mann–Whitney U test) compared to patients without depressive state; no significant difference in categorical variables between patients with and without depressive state (χ2 test).
AChR-Ab, antibodies against acetylcholine receptor; CSR, complete stable remission; I, improved; Kv1.4, voltage-gated potassium channel 1.4; MG-ADL, MG activities of daily living scale; MG composite, MG composite scale; MGFA, Myasthenia Gravis Foundation of America; MM, minimal manifestations; MuSK, muscle-specific tyrosine kinase; PR, pharmacologic remission; PSL, prednisolone; QMG, MGFA quantitative MG score; U, unchanged; W, worse.